Intellia Therapeutics Inc (NTLA): Next-Year EPS Estimate 41.30%
As of 2026-06-04, Intellia Therapeutics Inc (NTLA) has a next-year EPS growth estimate of 41.30%.
NTLA was first flagged by our screen on 2026-05-28, when analyst consensus for its next-year EPS growth was revised from 41.13% to 41.30%. Current-year growth is projected at 15.72%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 41.30%
- EPS growth this year
- 15.72%
- EPS next quarter (est)
- -$0.81
- Last price
- $14.75
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 41.30% | 15.72% | -$0.81 | $14.75 |
| 2026-06-03 | 41.30% | 15.72% | -$0.81 | $13.02 |
| 2026-06-02 | 41.30% | 15.72% | -$0.81 | $13.13 |
| 2026-06-01 | 41.30% | 15.72% | -$0.81 | $13.73 |
| 2026-05-31 | 41.30% | 15.72% | -$0.81 | $14.07 |
| 2026-05-28 | 41.30% | 15.72% | -$0.81 | $13.68 |
| 2026-05-27 | 41.13% | 15.47% | -$0.81 | $13.44 |
| 2026-05-26 | 41.13% | 15.47% | -$0.81 | $12.61 |
| 2026-05-25 | 41.13% | 15.47% | -$0.81 | $12.60 |
| 2026-05-24 | 41.13% | 15.47% | -$0.81 | $12.60 |
| 2026-05-21 | 39.60% | 15.02% | -$0.81 | $12.37 |
| 2026-05-20 | 39.60% | 15.02% | -$0.81 | $12.26 |
| 2026-05-19 | 39.60% | 15.02% | -$0.81 | $11.94 |
| 2026-05-18 | 39.60% | 15.02% | -$0.81 | $12.69 |
| 2026-05-17 | 39.60% | 15.02% | -$0.81 | $13.67 |
| 2026-05-14 | 39.60% | 15.02% | -$0.81 | $13.09 |
| 2026-05-13 | 39.60% | 15.02% | -$0.81 | $14.44 |
| 2026-05-12 | 42.68% | 13.76% | -$0.81 | $13.99 |
| 2026-05-11 | 43.10% | 10.90% | -$0.85 | $14.42 |
| 2026-05-10 | 41.71% | 6.58% | -$0.91 | $14.09 |
| 2026-05-07 | 41.71% | 6.58% | -$0.91 | $13.71 |
| 2026-05-06 | 41.71% | 6.58% | -$0.91 | $13.85 |
| 2026-05-05 | 41.71% | 6.58% | -$0.91 | $13.31 |
| 2026-05-04 | 41.71% | 6.58% | -$0.91 | $13.87 |
| 2026-05-03 | 41.71% | 6.58% | -$0.91 | $13.26 |
| 2026-04-30 | 40.57% | 6.50% | -$0.91 | $13.48 |
| 2026-04-29 | 43.68% | 6.01% | -$0.91 | $12.44 |
| 2026-04-28 | 43.68% | 6.01% | -$0.91 | $13.20 |
| 2026-04-27 | 43.68% | 6.01% | -$0.91 | $13.04 |
| 2026-04-26 | 44.69% | 5.05% | -$0.91 | $13.63 |
Recent News
- Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Intellia Stock Jumps 25%. A Key Trial Is Driving the RallyGuruFocus.com
- Intellia Therapeutics Shares Slip Despite Strong Phase 3 DataInvestorsHub
- This Biotech Just Lodged A First In Gene Editing; Why Analysts Are SplitInvestor's Business Daily
- Intellia seeks FDA approval for in vivo CRISPR therapyQuartz
- Intellia Stock Up on Gene-Editing Drug SuccessThe Wall Street Journal
- Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene EditingGlobeNewswire
- Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary AngioedemaGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Intellia Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Intellia Therapeutics Inc (NTLA) has a next-year EPS growth estimate of 41.30%, based on analyst consensus.
When was the latest EPS estimate revision for NTLA?▾
The most recent revision occurred on 2026-05-28, when analysts adjusted the next-year EPS growth estimate from 41.13% to 41.30%.
What sector and industry does Intellia Therapeutics Inc belong to?▾
Intellia Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NTLA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Intellia Therapeutics Inc (NTLA) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports